IP Verse

Cytotoxicity-Inducing Therapeutic Agent - EP2647707

The patent EP2647707 was granted to Chugai Seiyaku Kabushiki Kaisha on Sep 12, 2018. The application was originally filed on Nov 30, 2011 under application number EP11845786A. The patent is currently recorded with a legal status of "Revoked".

EP2647707

CHUGAI SEIYAKU KABUSHIKI KAISHA
Application Number
EP11845786A
Filing Date
Nov 30, 2011
Status
Revoked
Aug 4, 2023
Grant Date
Sep 12, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BOEHRINGER INGELHEIM RCV BOEHRINGER INGELHEIMJun 12, 2019HOFFMANN EITLEADMISSIBLE
GENMABJun 12, 2019J A KEMPADMISSIBLE
JAMES POOLEJun 12, 2019CARPMAELS & RANSFORDADMISSIBLE
MATHYS & SQUIREJun 12, 2019REDHOUSEADMISSIBLE
JANSSEN BIOTECHMay 24, 2019CARPMAELS & RANSFORDADMISSIBLE

Patent Citations (71) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0058481
DESCRIPTIONEP0133988
DESCRIPTIONEP0239400
DESCRIPTIONUS3773719
DESCRIPTIONUS4946778
DESCRIPTIONUS5260203
DESCRIPTIONWO03000883
DESCRIPTIONWO03104453
DESCRIPTIONWO2004022754
DESCRIPTIONWO2004065611
DESCRIPTIONWO2006006693
DESCRIPTIONWO2006106905
DESCRIPTIONWO2006132352
DESCRIPTIONWO2009011941
DESCRIPTIONWO8801649
DESCRIPTIONWO9201047
DESCRIPTIONWO9203918
DESCRIPTIONWO9220791
DESCRIPTIONWO9306213
DESCRIPTIONWO9311236
DESCRIPTIONWO9312227
DESCRIPTIONWO9319172
DESCRIPTIONWO9402602
DESCRIPTIONWO9411523
DESCRIPTIONWO9425585
DESCRIPTIONWO9501438
DESCRIPTIONWO9515388
DESCRIPTIONWO9602576
DESCRIPTIONWO9627011
DESCRIPTIONWO9633735
DESCRIPTIONWO9634096
INTERNATIONAL-SEARCH-REPORTWO2006106905
INTERNATIONAL-SEARCH-REPORTWO2008090960
INTERNATIONAL-SEARCH-REPORTWO2009041613
INTERNATIONAL-SEARCH-REPORTWO2009120922
INTERNATIONAL-SEARCH-REPORTWO2010034441
OPPOSITIONEP1870459
OPPOSITIONEP2194006
OPPOSITIONEP2194066
OPPOSITIONEP2445936
OPPOSITIONEP2576621
OPPOSITIONEP2647707
OPPOSITIONUS2003078385
OPPOSITIONUS2004002587
OPPOSITIONUS2005118174
OPPOSITIONUS2006235208
OPPOSITIONUS2008317758
OPPOSITIONUS2010178298
OPPOSITIONUS5585097
OPPOSITIONUS5624821
OPPOSITIONUS5648260
OPPOSITIONWO0042072
OPPOSITIONWO03035835
OPPOSITIONWO2004035607
OPPOSITIONWO2005063815
OPPOSITIONWO2005118635
OPPOSITIONWO2006020114
OPPOSITIONWO2006105338
OPPOSITIONWO2006106905
OPPOSITIONWO2007147901
OPPOSITIONWO2009041613
OPPOSITIONWO2009053368
OPPOSITIONWO2009080252
OPPOSITIONWO2009080253
OPPOSITIONWO2010085682
OPPOSITIONWO2010120561
OPPOSITIONWO2010151792
OPPOSITIONWO9627011
OPPOSITIONWO9850431
OPPOSITIONWO9958572
SEARCHWO2009053368

Non-Patent Literature (NPL) Citations (168) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ANAL. BIOCHEM., (1987), vol. 162, no. 1, pages 156 - 159-
DESCRIPTION- BIOCHEMISTRY, (1979), vol. 18, no. 24, pages 5294 - 5299-
DESCRIPTION- BIOPOLYMERS, (1983), vol. 22, pages 547 - 556-
DESCRIPTION- BLOOD, (1990), vol. 76, no. 1, pages 31 - 35-
DESCRIPTION- BLOOD, (2007), vol. 109, pages 1185 - 1192-
DESCRIPTION- CANCER IMMUNOL IMMUNOTHER, (2006), vol. 55, no. 5, pages 503 - 14-
DESCRIPTION- CANCER IMMUNOL IMMUNOTHER, (2007), vol. 56, no. 10, pages 1637 - 44-
DESCRIPTION- CANCER IMMUNOL IMMUNOTHER, (2009), vol. 58, no. 1, pages 95 - 109-
DESCRIPTION- CANCER SCI., (2010), vol. 101, no. 10, pages 2227 - 33-
DESCRIPTION- CANCER TREAT REV., (2010), vol. 36, no. 6, pages 458 - 67-
DESCRIPTION- CELL, (1976), vol. 8, no. 3, pages 405 - 415-
DESCRIPTION- CELL, (1989), vol. 57, no. 2, pages 277 - 285-
DESCRIPTION- CELL, (1990), vol. 60, no. 2, pages 225 - 234-
DESCRIPTION- CELL, (1990), vol. 61, no. 2, pages 341 - 350-
DESCRIPTION- CELL, (1994), vol. 77, no. 3, pages 391 - 400-
DESCRIPTION- C. EUR. J. IMMUNOL., (1976), vol. 6, no. 7, pages 511 - 519-
DESCRIPTION- CHEMTECH., (1982), vol. 12, pages 98 - 105-
DESCRIPTION- CLIN CANCER RES., (2010), vol. 16, no. 1, pages 11 - 20-
DESCRIPTION- CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY, (1978), vol. 81, pages 1 - 7-
DESCRIPTION- DAVIS ET AL., IMMUNOLOGICAL REVIEWS, (2002), vol. 190, pages 123 - 136-
DESCRIPTION- DRUG DES DEVEL THER, (2009), vol. 3, pages 7 - 16-
DESCRIPTION- DRUG DISCOV TODAY, (2005), vol. 10, no. 18, pages 1237 - 44-
DESCRIPTION- EBERT, K. M. ET AL., BIO/TECHNOLOGY, (1994), vol. 12, no. 7, pages 699 - 702-
DESCRIPTION- ED HARLOW; DAVID LANE, Antibodies: A Laboratory Manual, COLD SPRING HARBOR LABORATORY, (1988), pages 359 - 420-
DESCRIPTION- EMBO J., (1993), vol. 12, no. 7, pages 2645 - 53-
DESCRIPTION- Epitope Mapping Protocols in Methods in Molecular Biology, (1996), vol. 66-
DESCRIPTION- EXPERT OPIN BIOL THER, (2010), vol. 10, no. 8, pages 1259 - 69-
DESCRIPTION- FANTL ET AL., ANNU. REV. BIOCHEM., (1993), vol. 62, pages 453 - 481-
DESCRIPTION- FLOWER DR, BIOCHIM. BIOPHYS. ACTA, FLOWER (BIOCHIM. BIOPHYS. ACTA, (1999), vol. 1422, no. 3, pages 207 - 234-
DESCRIPTION- "Hormones and their Actions Part II", New Comprehensive Biochemistry, ELSEVIER SCIENCE PUBLISHERS BV., (1988), vol. 18B, pages 1 - 46-
DESCRIPTION- HUM. ANTIBOD. HYBRIDOMAS, (1990), vol. 1, no. 1, pages 47 - 54-
DESCRIPTION- INT J CANCER, (1988), vol. 41, no. 4, pages 609 - 15-
DESCRIPTION- INT J CANCER, (2003), vol. 103, no. 4, pages 455 - 65-
DESCRIPTION- J. BIOMED. MATER. RES., (1981), vol. 15, pages 267 - 277-
DESCRIPTION- J. EXP. MED., (1978), vol. 148, no. 1, pages 313 - 323-
DESCRIPTION- J. IMMUNOL., (1979), vol. 123, no. 4, pages 1548 - 1550-
DESCRIPTION- J. IMMUNOL. METHODS, (1980), vol. 35, no. 1-2, pages 1 - 21-
DESCRIPTION- J IMMUNOL. METHODS, (1999), vol. 231, no. 1-2, pages 177 - 189-
DESCRIPTION- J. MOL. RECOGNIT, (2003), vol. 16, pages 113 - 120-
DESCRIPTION- J. MOL. RECOGNIT., (2003), vol. 16, pages 113 - 120-
DESCRIPTION- JOURNAL OF IMMUNOLOGY, (1994), vol. 152, no. 11, pages 5368 - 5374-
DESCRIPTION- KOHLER; MILSTEIN ET AL., METHODS ENZYMOL., (1981), vol. 73, pages 3 - 46-
DESCRIPTION- MASSAGUE, CELL, (1992), vol. 69, no. 6, pages 1067 - 1070-
DESCRIPTION- MERCHANT AM ET AL., NAT. BIOTECHNOL., (1998), vol. 16, pages 677 - 681-
DESCRIPTION- MERCHANT AM ET AL., NATURE BIOTECHNOLOGY, (1998), vol. 16, pages 677 - 681-
DESCRIPTION- MILSTEIN C ET AL., NATURE, (1983), vol. 305, pages 537 - 540-
DESCRIPTION- MIYAJIMA ET AL., ANNU. REV. IMMUNOL., (1992), vol. 10, pages 295 - 331-
DESCRIPTION- NATURE, (1978), vol. 276, no. 5685, pages 269 - 270-
DESCRIPTION- NATURE, (1979), vol. 277, no. 5692, pages 131 - 133-
DESCRIPTION- NATURE, (1985), vol. 313, no. 6005, pages 756 - 761-
DESCRIPTION- NATURE, (1985), vol. 314, no. 6012, pages 628 - 31-
DESCRIPTION- NATURE BIOTECHNOLOGY, (1998), vol. 16, pages 677 - 681-
DESCRIPTION- NUCLEIC ACIDS RES., (1989), vol. 17, no. 8, pages 2919 - 2932-
DESCRIPTION- PATTHY, CELL, (1990), vol. 61, no. 1, pages 13 - 14-
DESCRIPTION- PLUCKTHUN, The Pharmacology of Monoclonal Antibodies, SPRINGER-VERLAG, (1994), vol. 113, pages 269 - 315-
DESCRIPTION- PROC. NATL. ACAD. SCI. USA, (1980), vol. 77, pages 4914 - 4917-
DESCRIPTION- PROC NATL ACAD SCI USA, (1986), vol. 83, no. 5, pages 1453 - 7-
DESCRIPTION- PROC. NATL. ACAD. SCI. USA., (1988), vol. 85, no. 10, pages 3435 - 3439-
DESCRIPTION- PROC. NATL. ACAD. SCI. U.S.A., (1988), vol. 85, no. 16, pages 5879 - 5883-
DESCRIPTION- PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, no. 23, pages 8998 - 9002-
DESCRIPTION- PROC. NATL. ACAD. SCI. USA., (1989), vol. 86, no. 1, pages 27 - 31-
DESCRIPTION- PROC. NATL. ACAD. SCI. USA., (1990), vol. 87, no. 22, pages 8702 - 8706-
DESCRIPTION- PROC. NATL. ACAD. SCI. USA, (1992), vol. 89, no. 12, pages 5640 - 5644-
DESCRIPTION- PROC. NATL. ACAD. SCI. USA, (1994), vol. 91, no. 2, pages 459 - 463-
DESCRIPTION- PROC NATL ACAD SCI USA., (1995), vol. 92, no. 15, pages 7021 - 5-
DESCRIPTION- PROC. NATL. ACAD. SCI. USA, (2006), vol. 103, no. 11, pages 4005 - 4010-
DESCRIPTION- PROTEIN ENGINEERING, (1996), vol. 9, no. 3, pages 299 - 305-
DESCRIPTION- Remington's Pharmaceutical Science, MARK PUBLISHING COMPANY-
DESCRIPTION- RIDGWAY JB ET AL., PROTEIN ENGINEERING, (1996), vol. 9, pages 617 - 621-
DESCRIPTION- SAMBROOK, J ET AL., Molecular Cloning, COLD SPRING HARBOR LAB. PRESS, (1989), pages 9.47 - 9.58-
DESCRIPTION- SATO, K. ET AL., CANCER RES., (1993), vol. 53, pages 851 - 856-
DESCRIPTION- SCIENCE, (1988), vol. 240, no. 4855, pages 1038 - 1041-
DESCRIPTION- SCIENCE, (2008), vol. 321, no. 5891, pages 974 - 7-
DESCRIPTION- Sequences of proteins of immunological interest, NIH PUBLICATION NO.91-3242-
DESCRIPTION- SMITH ET AL., CELL, (1994), vol. 76, no. 6, pages 959 - 962-
DESCRIPTION- TAGA ET AL., FASEB J., (1992), vol. 6, pages 3387 - 3396-
DESCRIPTION- TRENDS BIOTECHNOL, (2004), vol. 22, no. 5, pages 238 - 44-
DESCRIPTION- ULLRICH ET AL., CELL, (1990), vol. 61, no. 2, pages 203 - 212-
DESCRIPTION- VANDAMME ET AL., EUR. J. BIOCHEM., (1990), vol. 192, no. 3, pages 767 - 775-
INTERNATIONAL-SEARCH-REPORT- AMANN M ET AL., "Therapeutic window of an EpCAM/ CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM- expressing lymphocytes that is absent in humans", CANCER IMMUNOL. IMMUNOTHER., (2009), vol. 58, no. 1, pages 95 - 109, XP019654574-
INTERNATIONAL-SEARCH-REPORT- MASAMI SUZUKI, "Kotai Iyakuhin no Kenkyu Kaihatsu", NISSEIKEN TAYORI, (20100701), vol. 56, no. 4, pages 45 - 51, XP008168904-
INTERNATIONAL-SEARCH-REPORT- SEBASTIAN M ET AL., "Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study", CANCER IMMUNOL. IMMUNOTHER., (2007), vol. 56, no. 10, pages 1637 - 1644, XP019539101
INTERNATIONAL-SEARCH-REPORT- TEERINEN T ET AL., "Structure-based stability engineering of the mouse IgG1 Fab fragment by modifying constant domains", J. MOL. BIOL., (2006), vol. 361, no. 4, pages 687 - 697, XP024951313
INTERNATIONAL-SEARCH-REPORT- MERCHANT AM ET AL., "An efficient route to human bispecific IgG", NAT. BIOTECHNOL., (1998), vol. 16, no. 7, pages 677 - 681, XP002141015
INTERNATIONAL-SEARCH-REPORT- MCEARCHERN JA ET AL., "Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities", BLOOD, (2007), vol. 109, no. 3, pages 1185 - 1192, XP008123428
INTERNATIONAL-SEARCH-REPORT- IZUMI KUMAGAI ET AL., "Humanized bispecific antibodies retargeting of lymphocytes against tumor cells", DRUG DELIVERY SYSTEM, (2008), vol. 23, no. 5, pages 518 - 525, XP055108472
OPPOSITION- AMANN et al., "Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans", Cancer Immunol. Immunother., (20080702), vol. 58, no. 1, pages 95 - 109, XP019654574-
OPPOSITION- "Chapter 22", Das & Suresh, Methods and Protocols in Molecular Medicine. Adoptive Immunotherapy: Methods and Protocols, Press Inc., (20050000), vol. 109, pages 329 - 345, XP055606106-
OPPOSITION- "Choice of constant region", Siegfried Matzku et al, ANTIBODIES IN DIAGNOSIS AND THERAPY, Harwood academic, (19990000), page 7, ISBN 90-5702-310-5, XP055606240-
OPPOSITION- David J King, APPLICATIONS AND ENGINEERING OF MONOCLONAL ANTIBODIES, (2005), pages 146 - 147, ISBN 0-203-26917-9, XP055606239-
OPPOSITION- DAVID J. KING, APPLICATIONS AND ENGINEERING OF MONOCLONAL ANTIBODIES, Taylor & Francis, (20050000), pages 146 - 147, ISBN 0-203-26917-9, XP055606239-
OPPOSITION- DEMANET et al., "Treatment of Murine B Cell Lymphoma with Bispecific monoclonal Antibodies (Anti-Idiotype x Anti-CD3)", The Journal of Immunology, (19910801), vol. 147, no. 3, pages 1091 - 1097, XP055613384-
OPPOSITION- HAAGEN et al., "EVALUATION OF FCGAMMA RECEPTOR MEDIATED T-CELL ACTIVATION BY TWO PURIFIED CD3 X CD19 BISPECIFIC MONOCLONAL ANTIBODIES WITH HYBRID FC DOMAINS", Therapeutic Immunology, (19940000), vol. 1, no. 5, pages 279 - 287, XP000914606-
OPPOSITION- HAAGEN IA et al., "Interaction of human monocyte Fc gamma receptors with rat IgG2b. A new indicator for the Fc gamma RIIa (R-H131) polymorphism", J Immunol., (19950215), vol. 154, no. 4, pages 1852 - 1860, XP002139562-
OPPOSITION- LEHNINGER, Principles of Biochemistry, 5th ed., (20080000), page 171, XP055612075-
OPPOSITION- Luis Graca, THE IMMUNE SYNAPSE AS A NOVEL TARGET FOR THERAPY, (20080000), pages 59 - 61, ISBN 978-3-7643-8295-7, XP055606241-
OPPOSITION- Melvyn Little, Recombinant Antibodies for Immunotherapy, (20090000), pages 133 - 134, ISBN 978-0-521-88732-8, XP055606242-
OPPOSITION- SEIMETZ et al., "Development and approval of the trifunctional antibody catumaxomab (anti-EpCAMxanti-CD3) as a targeted cancer immunotherapy", Cancer Treatment Reviews, (20101000), vol. 36, no. 6, pages 458 - 467, XP027256157-
OPPOSITION- SHAHABUDDIN S et al., "Lymphocyte subset reference ranees in healthv Saudi Arabian children", Pediatr Allergy Immunol., (19980200), vol. 9, no. 1, pages 44 - 48, XP055612078-
OPPOSITION- Siegfried Matzku et al., Antibodies in Diagnosis and Therapy, (19990000), page 7, ISBN 90-5702-310-5, XP055606240-
OPPOSITION- STRAUSS et al., "Without prior stimulation, tumor-associated lymphocytes from malignant effusions lyse autologous tumor cells in the presence of bispecific antibody HEA125xOKT3", Clinical Cancer Research, (19990000), vol. 5, pages 171 - 180, XP002190776-
OPPOSITION- Strauß G. et al., "Without Prior Stimulation, Tumor-associated Lymphocytes from Malignant Effusions Lyse Autologous Tumor Cells in the Presence of Bispecific Antibody HEA125xOKT3", Clinical Cancer Research, (19990100), vol. 5, no. 1, pages 171 - 180, XP002190776-
OPPOSITION- "Table 1", LUIS GRACA, THE IMMUNE SYNAPSE AS A NOVEL TARGET FOR THERAPY, Birkhäuser, (20080000), pages 59 - 61, ISBN 978-3-7643-8295-7, XP055606241-
OPPOSITION- THAKUR A et al., "Cancer therapy with bispecific antibodies: Clinical experience", Curr Opin Mol Ther, (20100600), vol. 12, no. 3, pages 340 - 349, XP009145639-
OPPOSITION- THAKUR et al., "Cancer therapy with bispecific antibodies: Clinical experience", Current Opinion in Molecular Therapeutics, (20100601), vol. 12, no. 3, pages 340 - 349, XP009145639-
OPPOSITION- "The Role of the Fe Region", Roland E. Kontermann, Bispecific Antibodies, Springer, (20110000), pages 296 - 298, ISBN 978-3-642-20909-3, XP055606245-
OPPOSITION- "Unit 2.13 Production of Bispecific Antibodies", David M. Segal and Bert J.E.G. Bast, Current Protocols in Immunology, John Wiley & Sons, Inc., (19950000), pages 2.13.1 - 2.13.16, XP055606097-
OPPOSITION- "Use of lgG lsotypes", Melvyn Little, Recombinant Antibodies for Immunotherapy, CAMBRIDGE UNIVERSITY PRESS, (20090000), pages 133 - 134, ISBN 978-0-521-88732-8, XP055606242-
OPPOSITION- WEINER G. J., ET AL., "THE ROLE OF T CELL ACTIVATION IN ANTI-CD3 X ANTITUMOR BISPECIFIC ANTIBODY THERAPY.", The Journal of Immunology, Williams & Wilkins Co., US, US, (19940101), vol. 152., ISSN 0022-1767, pages 2385 - 2392., XP002048527-
OPPOSITION- WINES et al., "The IgG Fc contains distinct Fc receptor (FcR) binding sites: The leukocyte receptors Fc[gamma]RI and Fc[gamma]RIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein A", J. Immunol., (20000000), vol. 164, no. 10, pages 5313 - 5318, XP002381581-
OPPOSITION- WOLF et al., "BiTEs: bispecific antibody constructs with unique anti-tumor activity", Drug Discovery Today, (20050915), vol. 10, no. 18, pages 1237 - 1244, XP027684780-
OPPOSITION- NITTA et al., "BISPECIFIC F(AB')2 MONOMER PREPARED WITH ANTI-CD3 AND ANTI-TUMOR MONOCLONAL ANTIBODIES IS MOST POTENT IN INDUCTION OF CYTOLYSIS OF HUMAN T CELLS", Eur J Immunol, (19890000), vol. 19, pages 1437 - 1441, XP000647744
OPPOSITION- ROUTLEDGE E G; ET AL, "A HUMANIZED MONOVALENT CD3 ANTIBODY WHICH CAN ACTIVATE HOMOLOGOUS COMPLEMENT", European Journal of Immunology, (19911101), vol. 21, pages 2717 - 2725, XP000350634
OPPOSITION- BOLT S., ET AL., "THE GENERATION OF A HUMANIZED, NON-MITOGENIC CD3 MONOCLONAL ANTIBODY WHICH RETAINS IN VIRTO IMMUNUSUPPRESSIVE PROPERTIES.", European Journal of Immunology, Wiley VCH, Weinheim, Weinheim, (19930201), vol. 23., no. 02., doi:10.1002/eji.1830230216, ISSN 0014-2980, pages 403 - 410., XP000561698
OPPOSITION- LINK BRIAN K; ET AL, "Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms", International Journal of Cancer, (19980000), vol. 77, pages 251 - 256, XP002206270
OPPOSITION- ARMOUR et al., "Recombinant human IgG molecules lacking Fc.gamma. receptor I binding and monocyte triggering activities", European Journal of Immunology, (19990801), vol. 29, no. 8, pages 2613 - 2624, XP002116082
OPPOSITION- ARMOUR KL et al., "Recombinant human IgG molecules lacking Fc.gamma. receptor I binding and monocyte triggering activities", Eur J Immunol., (19990800), vol. 29, no. 8, pages 2613 - 2624, XP002116082
OPPOSITION- ARMOUR K L; ET AL, "Recombinant human IgG molecules lacking Fc.gamma. receptor I binding and monocyte triggering activities", European Journal of Immunology,, (19990000), vol. 29, pages 2613 - 2624, XP002116082
OPPOSITION- XU DANLIN; ET AL, "In vitro characterization of five humanized OKT3 effector function variant antibodies", CELLULAR IMMUNOLOGY, (2000225), vol. 200, no. 1, pages 16 - 26, XP002376698
OPPOSITION- XU et al., "In vitro characterization of five humanized OKT3 effector function variant antibodies", Cellular Immunology, (20000000), vol. 200, pages 16 - 26, XP002376698
OPPOSITION- THOMAS A K, ET AL., "A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enable rapid expansion and long-term growth of CD4 T lymphocytes", CLINICAL IMMUNOLOGY, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20021203), vol. 105, no. 3, doi:10.1006/clim.2002.5277, ISSN 1521-6616, pages 259 - 272, XP002971111
OPPOSITION- DE GAST GC et al., "CD8 T cell activation after intravenous administration of CD3 x CD19 bispecific antibody in patients with non-Hodgkin lymphoma", Cancer Immunol Immunother, (19950600), vol. 40, no. 6, pages 390 - 396, XP008178799
OPPOSITION- SEBASTIAN et al., "Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM anti-CD3): a phase I study", Cancer Immunol. Immunother., (20070405), vol. 56, no. 10, pages 1637 - 1644, XP019539101
OPPOSITION- SEBASTIAN M et al., "Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM anti-CD3): a phase I study", Cancer Immunol Immunother, (20071000), vol. 56, no. 10, pages 1637 - 1644, XP019539101
OPPOSITION- Parren P W H I; Geerts M E J; Boeije L C M; Aarden L A, "Induction of T-cell proliferation by recombinant mouse and chimeric mouse/human anti-CD3 monoclonal antibodies", Research in Immunology,, (1991), vol. 142, no. 9, pages 749 - 763, XP023924339
OPPOSITION- NAKANO et al., "Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells", Biochemical and Biophysical Research Comm., (20090901), vol. 378, no. 2, pages 279 - 284, XP025745445
OPPOSITION- Leonard G Presta, "Molecular engineering and design of therapeutic antibodies", CURRENT OPINION IN IMMUNOLOGY, (20080000), vol. 20, no. 4, pages 460 - 470, XP023612046
OPPOSITION- PRESTA et al., "Molecular engineering and design of therapeutic antibodies", Current Opinion in Immunology, (20080801), vol. 20, no. 4, pages 460 - 470, XP025771205
OPPOSITION- Presta LG, "Molecular engineering and design of therapeutic antibodies", Curr Opin Immunol, vol. 20, no. 4, pages 460 - 470, XP025771205
OPPOSITION- STROHL, "Available online at www.sciencedirect.comOptimization of Fc-mediated effector functions of monoclonalantibodies", Current Opinion in Biotechnology, (20091104), vol. 20, no. 6, pages 685 - 691, XP026778879
OPPOSITION- STROHL, "Optimization of Fc-mediated effector functions of monoclonal antibodies", Current Opinion in Biotechnology, (20090000), vol. 20, pages 685 - 691, XP026778879
OPPOSITION- MOLHOJ et al., "CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis", Molecular Immunology, (20061201), vol. 44, no. 8, pages 1935 - 1943, XP005792730
OPPOSITION- CARTER PAUL, "Bispecific human IgG by design.", JOURNAL OF IMMUNOLOGICAL METHODS., ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM., NL, NL, (20010101), vol. 248, no. 1-2, doi:10.1016/S0022-1759(00)00339-2, ISSN 0022-1759, pages 7 - 15, XP002974199
OPPOSITION- SEGAL DM et al., "Bispecific antibodies in cancer therapy", Curr Opin Immunol., (19991000), vol. 11, no. 5, pages 558 - 562, XP004257585
OPPOSITION- SEGAL et al., "Bispecific antibodies in cancer therapy", Current Opinion In Immunology, (19991001), vol. 11, no. 5, pages 558 - 562, XP004257585
OPPOSITION- MERCHANT AM et al., "An efficient route to human bispecific IgG", Nat Biotechnol., (19980700), vol. 16, no. 7, pages 677 - 681, XP002141015
OPPOSITION- MERCHANT et al., "An efficient route to human bispecific IgG", Nat. Biotechnol., (19980701), vol. 16, no. 7, pages 677 - 681, XP002141015
OPPOSITION- MERCHANT et al., "An efficient route to human bispecific IgG", Nature Biotechnology, (19980000), vol. 16, no. 7, pages 677 - 681, XP002141015
OPPOSITION- CARTER P J, "POTENT ANTIBODY THERAPEUTICS BY DESIGN", NATURE REVIEWS IMMUNOLOGY, Nature Pub. Group, GB, GB, (20060407), vol. 6, doi:10.1038/nri1837, ISSN 1474-1733, pages 343 - 357, XP007901440
OPPOSITION- NIMMERJAHN et al., "Fcγ receptors as regulators of immune responses", Nature Reviews, (20080101), vol. 8, pages 34 - 47, XP002691307
OPPOSITION- ZEIDLER R et al., "THE FC-REGION OF A NEW CLASS OF INTACT BISPECIFIC ANTIBODY MEDIATESACTIVATION OF ACCESSORY CELLS AND NK CELLS AND INDUCES DIRECT PHAGOCYTOSIS OF TUMOUR CELLS", Br J Cancer, (20000700), vol. 83, no. 2, pages 261 - 266, XP001053758
OPPOSITION- SHIELDS et al., "High resolution mapping of the binding site on human IgG1 for FcgammaRI, FcgammaRII, FcgammaRIII, and FcRn and design of IgG1 variants with improved binding to the FcgammaR", The Journal of Biological Chemistry, (20010000), vol. 276, no. 9, pages 6591 - 6604, XP002271092
OPPOSITION- RIDGWAY et al., "'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization", Protein Eng., (19960000), vol. 9, no. 7, pages 617 - 621, XP002610995
OPPOSITION- OGANESYAN et al., "Structural characterization of a human Fc fragment engineered for lack of effector functions", Acta Crystallographica, (20080000), vol. D64, pages 700 - 704, XP009108181
OPPOSITION- ASCHERMANN et al., "The other side of immunoglobulin G: suppressor of inflammation", Clinical & Experimental Immunology, (20090000), vol. 160, no. 2, pages 161 - 167, XP055613388
OPPOSITION- VAN LOGHEM et al., "Staphyloccocal protein A and human IgG subclasses and allotypes", Scand. J. Immunol., (19820000), vol. 15, pages 275 - 278, XP008112596
OPPOSITION- SALINIKOV et al., "Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma", J. Cell . Mol. Med., (20090901), vol. 13, no. 9B, pages 4023 - 4033, XP055606247
OPPOSITION- SALNIKOV et al., "Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma", J. Cell . Mol. Med., (20090000), vol. 13, no. 9B, pages 4023 - 4033, XP055606247
OPPOSITION- KONTERMANN ROLAND E, "Recombinant bispecific antibodies for cancer therapy", Acta Pharmacologica Sinica, Nature Publishing Group, GB, GB, (20050101), vol. 26, no. 1, doi:10.1111/j.1745-7254.2005.00008.x, ISSN 1671-4083, pages 1 - 9, XP002426874
OPPOSITION- ISHIGURO et al., "An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors", Sci. Transl. Med., (201710040), vol. 9, no. 410, page eaal4291, XP055606251
OPPOSITION- HEZAREH et al., "Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1", Journal of Virology, (20011200), vol. 75, no. 24, pages 12161 - 12168, XP002339184
OPPOSITION- MCEEARCHERN et al., "Engineerd anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities", Blood, (200702001), vol. 109, no. 3, pages 1185 - 1192, XP008123428
OPPOSITION- ZHAO XIAOBIN, ET AL, "Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical", Blood, American Society of Hematology, US, US, (20071001), vol. 110, no. 7, doi:10.1182/blood-2006-12-062927, ISSN 0006-4971, pages 2569 - 2577, XP002543677
OPPOSITION- STROEHLEIN et al., "Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis", Journal of Experimental & Clinical Cancer Research, (20090214), vol. 28, no. 1, page 18, XP021052973
OPPOSITION- Kasthuri Raj S; Taubman Mark B; Mackman Nigel, "Role of tissue factor in cancer", Journal of Clinical Oncology, (20091010), vol. 27, no. 29, pages 4834 - 4838, XP008158901
OPPOSITION- Kevin O. Saunders, Kevin O Saunders, "Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life", Frontiers in Immunology, (20190101), vol. 10, doi:10.3389/fimmu.2019.01296, page 1296, XP055654839
OPPOSITION- HINTON et al., "An engineered human IgG1 antibody with longer serum half-life", J Immunol, (20060000), vol. 176, pages 346 - 356, XP002482524
OPPOSITION- AN et al., "IgG2m4, an engineered antibody isotype with reduced Fc function", mAbs, (20091100), vol. 1, no. 6, pages 572 - 579, XP002665505
OPPOSITION- BRENNAN et al., "Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies", Mabs, (20105000), vol. 2, no. 3, pages 233 - 255, XP055072297
OPPOSITION- CHELIUS D et al., "Structural and functional characterization of the trifunctional antibody catumaxomab", MAbs, (20100500), vol. 2, no. 3, pages 309 - 319, XP009137730
SEARCH- THAKUR ARCHANA ET AL, "Cancer therapy with bispecific antibodies: Clinical experience", CURRENT OPINION IN MOLECULAR THERAPEUTICS, THOMSON REUTERS (SCIETIFIC) LTD, (20100601), vol. 12, no. 3, ISSN 2040-3445, pages 340 - 349, XP009145639 [Y] 1-15 * the whole document *-
SEARCH- WOLF E ET AL, "BiTEs: bispecific antibody constructs with unique anti-tumor activity", DRUG DISCOVERY TODAY, ELSEVIER, RAHWAY, NJ, US, vol. 10, no. 18, ISSN 1359-6446, (20050915), pages 1237 - 1244, (20050915), XP027684780 [Y] 1-15 * the whole document *-
SEARCH- ARMOUR K L ET AL, "Recombinant human IgG molecules lacking Fc.gamma. receptor I binding and monocyte triggering activities", EUROPEAN JOURNAL OF IMMUNOLOGY, WILEY - V C H VERLAG GMBH & CO. KGAA, DE, (19990801), vol. 29, no. 8, doi:10.1002/(SICI)1521-4141(199908)29:08<2613::AID-IMMU2613>3.0.CO;2-J, ISSN 0014-2980, pages 2613 - 2624, XP002116082 [Y] 1-15 * the whole document *
SEARCH- NAKANO K ET AL, "Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 378, no. 2, doi:10.1016/J.BBRC.2008.11.033, ISSN 0006-291X, (20090109), pages 279 - 284, (20081118), XP025745445 [Y] 1-15 * the whole document *
SEARCH- PRESTA ET AL, "Molecular engineering and design of therapeutic antibodies", CURRENT OPINION IN IMMUNOLOGY, ELSEVIER, OXFORD, GB, vol. 20, no. 4, doi:10.1016/J.COI.2008.06.012, ISSN 0952-7915, (20080801), pages 460 - 470, (20080806), XP025771205 [A] 1-15
SEARCH- MOLHOJ ET AL, "CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis", MOLECULAR IMMUNOLOGY, PERGAMON, GB, (20061201), vol. 44, no. 8, doi:10.1016/J.MOLIMM.2006.09.032, ISSN 0161-5890, pages 1935 - 1943, XP005792730 [Y] 1-15 * the whole document, in particular "Abstract" and "Discussion" *
SEARCH- SEGAL D M ET AL, "Bispecific antibodies in cancer therapy", CURRENT OPINION IN IMMUNOLOGY, ELSEVIER, OXFORD, GB, (19991001), vol. 11, no. 5, doi:10.1016/S0952-7915(99)00015-1, ISSN 0952-7915, pages 558 - 562, XP004257585 [Y] 1-15 * the whole document *
SEARCH- STROEHLEIN MICHAEL A ET AL, "Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis", JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, BIOMED CENTRAL LTD, LONDON UK, (20090214), vol. 28, no. 1, doi:10.1186/1756-9966-28-18, ISSN 1756-9966, page 18, XP021052973 [Y] 1-15 * the whole document, in particular "Abstract", p.3 and "Discussion" *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents